Ruxolitinib (Jakafi)

ruxolitinib · Incyte

Drug timelines are a Plus or Pro feature.

13 regulatory and trial events tracked for Ruxolitinib (Jakafi), covering 2018-05-11 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure [Phase 1, Phase 2]